Long-Term Electrocardiographic Changes and Clinical Outcomes of Transcatheter Aortic Valve Implantation Recipients Without New Postprocedural Conduction Disturbances.


Journal

The American journal of cardiology
ISSN: 1879-1913
Titre abrégé: Am J Cardiol
Pays: United States
ID NLM: 0207277

Informations de publication

Date de publication:
01 01 2020
Historique:
received: 21 08 2019
revised: 19 09 2019
accepted: 19 09 2019
pubmed: 17 11 2019
medline: 17 4 2020
entrez: 17 11 2019
Statut: ppublish

Résumé

The objective of this study was to determine the long-term (>1 year) electrocardiographic (ECG) and clinical outcomes of patients without significant changes in their electrocardiogram after transcatheter aortic valve implantation (TAVI; including patients with pre-existing ECG abnormalities). Among 772 consecutive patients who underwent TAVI in our institution, 397 patients (51%) without new ECG changes were included. TAVI patients were divided into 2 groups according to the presence of pre-existing ECG-conduction disturbances (ECG-CD: 140 patients, non-ECG-CD: 257 patients). Clinical follow-up (median: 35 [22 to 57] months) was complete in all patients but 5 (1.2%), and ECG data were available in 291 patients (84.3% of patients at risk) at a median of 29 (20 to 50) months. In the non-ECG-CD group, most patients (79.8%) remained without significant ECG changes at follow-up, and 16.9% developed first-degree atrioventricular block and/or bundle branch block over time. The rate of permanent pacemaker (PPM) implantation at follow-up was 3.5% (1.1%/year) in the non-ECG-CD group versus 15.7% (5.5%/year) in the ECG-CD group (p <0.001). The presence of pre-existing CD was an independent predictor of PPM at follow-up (hazard ratio [HR] 4.67, 95% confidence interval [CI] 2.15 to 10.16, p <0.001). The ECG-CD group exhibited a higher risk of heart failure hospitalization (non-ECG-CD: 25%, ECG-CD: 29%, log-rank p = 0.01), but not mortality (non-ECG-CD: 50%, ECG-CD: 46%, log-rank p = 0.60) at 5-year follow-up. In conclusion, the ECG remained unchanged in most TAVI recipients without new postprocedural CD. Pre-existing ECG-CD was associated with an increased risk of PPM and heart failure hospitalization at long-term follow-up. These results provide reassuring data in the era of TAVI expanding toward candidates with a longer life expectancy, and highlight the importance of a closer follow-up of those patients with pre-existing ECG-CDs.

Identifiants

pubmed: 31732136
pii: S0002-9149(19)31117-8
doi: 10.1016/j.amjcard.2019.09.047
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

107-113

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Guillem Muntané-Carol (G)

Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada.

Marcel Alméndarez (M)

Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada.

Lucia Junquera (L)

Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada.

Jerome Wintzer-Wehekind (J)

Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada.

David Del Val (D)

Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada.

Laurent Faroux (L)

Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada.

Robert Delarochellière (R)

Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada.

Jean-Michel Paradis (JM)

Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada.

Eric Dumont (E)

Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada.

Dimitri Kalavrouziotis (D)

Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada.

Siamak Mohammadi (S)

Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada.

Melanie Côté (M)

Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada.

François Philippon (F)

Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada.

Josep Rodés-Cabau (J)

Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada. Electronic address: josep.rodes@criucpq.ulaval.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH